Search
Showing results for "1"
ORIGINS has several sub-projects exploring allergy development within the cohort, with a focus on nutritional strategies for allergy prevention.
Find answers to frequently asked questions about ORIGINS.
Research
The global epidemiology of impetigo: A systematic review of the population prevalence of impetigo and pyodermaWe conducted a comprehensive, systematic review of the global childhood population prevalence of impetigo and the broader condition pyoderma.
Our team aims to optimise lung health early in life to ensure the best possible health outcomes later in life.
Learn about our timepoints for online questionnaires and Kids Check Appointments.
Research
Small-molecule screen reveals synergy of cell cycle checkpoint kinase inhibitors with DNA-damaging chemotherapies in medulloblastomaMedulloblastoma (MB) consists of four core molecular subgroups with distinct clinical features and prognoses. Treatment consists of surgery, followed by radiotherapy and cytotoxic chemotherapy. Despite this intensive approach, outcome remains dismal for patients with certain subtypes of MB, namely, MYC-amplified Group 3 and TP53-mutated SHH. Using high-throughput assays, six human MB cell lines were screened against a library of 3208 unique compounds. We identified 45 effective compounds from the screen and found that cell cycle checkpoint kinase (CHK1/2) inhibition synergistically enhanced the cytotoxic activity of clinically used chemotherapeutics cyclophosphamide, cisplatin, and gemcitabine.
Research
Incidence of acute rheumatic fever in northern and western Uganda: a prospective, population-based studyAcute rheumatic fever is infrequently diagnosed in sub-Saharan African countries despite the high prevalence of rheumatic heart disease. We aimed to determine the incidence of acute rheumatic fever in northern and western Uganda.
Research
The Platform trial In COVID-19 vaccine priming and BOOsting (PICOBOO) booster vaccination substudy protocolCoronavirus-2019 (COVID-19) vaccination in Australia commenced in February 2021. The first vaccines recommended for use were AZD1222 and BNT162b2, both delivered as a two-dose primary schedule. In the absence of sustained immunity following immunisation, recommendations for booster vaccination have followed. It is likely that periodic boosting will be necessary for at least some Australians, but it is unknown what the optimal booster vaccines and schedules are or for whom vaccination should be recommended.
Research
The Importance of Scabies Co-Infection in the Treatment Considerations for ImpetigoTreatment success for scabies co-infection was lower than for impetigo overall, with a higher success seen in the co-trimoxazole group than benzylpenicillin
News & Events
New research reveals crushing burden of Tourette syndrome and related disordersImpact for Tourette's, the first survey of its kind in Australia provides comprehensive national data on the daily challenges faced by children and adults living with tic-related disorders like Tourette syndrome